Home › Funds › ORBIMED ADVISORS LLC › PVLA
ORBIMED ADVISORS LLC position in PVLA
PALVELLA THERAPEUTICS INC NE · Health Care
ORBIMED ADVISORS LLC reported holding 229,860 shares of PVLA (PALVELLA THERAPEUTICS INC NE) in its Q3 2026 13F filing — a position valued at US$31.7M, representing 0.65% of its reported portfolio and ranking #37 among its reported holdings. ORBIMED ADVISORS LLC has disclosed PVLA holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How ORBIMED ADVISORS LLC's PVLA position evolved
ORBIMED ADVISORS LLC first disclosed a stake in PVLA in Q1 2026 at 50,000 shares (US$6.2M). The position peaked in Q3 2026 at 229,860 shares, worth US$31.7M. Across 3 filings, ORBIMED ADVISORS LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 229,860 shares valued at US$31.7M — an increase of 189,860 shares quarter over quarter.. Notable position changes include a 475% increase in Q3 2026 (shares rose 5% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 50.00K | $6.23M | New |
| Q2 2026 | 40.00K | $6.11M | Reduce |
| Q3 2026 | 229.86K | $31.70M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PVLA and 13F data
PVLA (PALVELLA THERAPEUTICS INC NE) is a Health Care company. 68 other funds we track also report a position in PVLA — the largest reported positions include MONTANOVA CAPITAL, LLC (US$144.1M), Frazier Life Sciences Management, L.P. (US$121.7M), First Light Asset Management, LLC (US$101.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PVLA
- MONTANOVA CAPITAL, LLC 1.04M sh · $144.12M · Q3 2026
- Frazier Life Sciences Management, L.P. 882.40K sh · $121.71M · Q3 2026
- First Light Asset Management, LLC 734.09K sh · $101.25M · Q3 2026
- BVF INC/IL 607.15K sh · $83.74M · Q3 2026
- EMERALD ADVISERS, LLC 229.40K sh · $31.64M · Q3 2026
- Siren, L.L.C. 207.49K sh · $28.62M · Q3 2026
- MPM BioImpact LLC 197.63K sh · $27.26M · Q3 2026
- First Turn Management, LLC 109.87K sh · $15.15M · Q3 2026
- Clio Asset Management LLC 86.01K sh · $11.86M · Q3 2026
- NEXTBio Capital Management LP 80.41K sh · $11.09M · Q3 2026
- AWM Investment Company, Inc. 69.42K sh · $9.57M · Q3 2026
- NAN FUNG TRINITY (HK) Ltd 52.63K sh · $7.26M · Q3 2026
More on ORBIMED ADVISORS LLC
FAQ
How long has ORBIMED ADVISORS LLC held PVLA?
ORBIMED ADVISORS LLC has disclosed PVLA holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is ORBIMED ADVISORS LLC's current position in PVLA?
As of Q3 2026, ORBIMED ADVISORS LLC holds 229.86K shares of PVLA (PALVELLA THERAPEUTICS INC NE), valued at $31.70M, representing 0.65% of its reported portfolio and ranking #37.
Has ORBIMED ADVISORS LLC been buying or selling PVLA?
In the latest 13F filing (Q3 2026), ORBIMED ADVISORS LLC increased its position in PVLA. The position peaked in Q3 2026 at 229.86K shares.
Which other funds hold PVLA?
Other major institutional holders of PVLA include MONTANOVA CAPITAL, LLC, Frazier Life Sciences Management, L.P., First Light Asset Management, LLC, among 68 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.